TA-65

DIETARY_SUPPLEMENT3 trials

Sponsors

University of Connecticut, Medical College of Wisconsin

Conditions

AgingInsulin ResistanceMetabolic SyndromeMetabolic Syndrome XTelomere ShorteningVascular Diseases

Phase 1

The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome

TerminatedNCT01753674

University of ConnecticutInsulin Resistance, Metabolic Syndrome

Start: 2013-01-31End: 2014-06-30Updated: 2015-05-28

Unknown Phase

Effects of TA-65, a Telomerase Activator on Metabolic Syndrome

CompletedNCT02531334

University of ConnecticutMetabolic Syndrome X

Start: 2015-08-31End: 2018-06-30Target: 40Updated: 2018-10-10

TA-65 and Aging Associated Microvascular Dysfunction

Not yet recruitingNCT05598359

Medical College of WisconsinAging, Telomere Shortening, Vascular Diseases

Start: 2027-01-01End: 2029-12-31Target: 180Updated: 2026-05-01